Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- The Kirklin Clinic at Acton Road — Birmingham, Alabama
- Lewis and Faye Manderson Cancer Center — Tuscaloosa, Alabama
+ 385 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tum…
Sponsor: NRG Oncology
NCT ID: NCT04134260
Locations: - Cancer Center at Saint Joseph's — Phoenix, Arizona
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Kaiser Permanente-Anaheim — Anaheim, California
+ 342 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Locations: - Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska
- Alaska Oncology and Hematology LLC — Anchorage, Alaska
+ 339 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Locations: - Banner MD Anderson Cancer Center — Gilbert, Arizona
- Cancer Center at Saint Joseph's — Phoenix, Arizona
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
+ 331 more sites in the U.S.
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Locations: - Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska
- Alaska Oncology and Hematology LLC — Anchorage, Alaska
+ 319 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Locations: - Banner University Medical Center - Tucson — Tucson, Arizona
- University of Arizona Cancer Center-North Campus — Tucson, Arizona
- Kaiser Permanente Dublin — Dublin, California
+ 183 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body i…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06470243
Locations: - Highlands Oncology Group - Fayetteville — Fayetteville, Arkansas
- Highlands Oncology Group - Rogers — Rogers, Arkansas
- Highlands Oncology Group — Springdale, Arkansas
+ 171 more sites in the U.S.
Phase 3 Recruiting Industry
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Sponsor: AstraZeneca
NCT ID: NCT06120491
Locations: - Research Site — Chandler, Arizona
- Research Site — Gilbert, Arizona
- Research Site — Phoenix, Arizona
+ 115 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Locations: - The University of Arizona Cancer Center - North Campus ( Site 0073) — Tucson, Arizona
- UCLA Hematology/Oncology - Santa Monica ( Site 0044) — Los Angeles, California
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040) — Orange, California
+ 56 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
Sponsor: Celgene
NCT ID: NCT06764485
Locations: - Central Alabama Research — Birmingham, Alabama
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Local Institution - 0370 — Anaheim, California
+ 52 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Locations: - University of California at San Diego — La Jolla, California
- Ronald Reagan UCLA Medical Center — Los Angeles, California
- Rocky Mountain Cancer Centers — Aurora, Colorado
+ 46 more sites in the U.S.
Phase 3 Recruiting Network
This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06235697
Locations: - Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- Kaiser Permanente Dublin — Dublin, California
- Kaiser Permanente-Fremont — Fremont, California
+ 43 more sites in the U.S.